-
公开(公告)号：US10363278B2
公开(公告)日：2019-07-30
申请号：US15381044
申请日：2016-12-15
申请人： Amnio Technology LLC
IPC分类号： A61K35/50 , A61F9/00 , A61J1/14 , A61K8/98 , A61K9/14 , A61K35/28 , A61K35/35 , A61K35/44 , A61K47/20 , A61K47/46 , A61M11/00 , A61M5/178 , A61Q19/08 , C12N5/073 , A61K35/545
摘要： A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at −20° C. for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.
-
公开(公告)号：US11207355B2
公开(公告)日：2021-12-28
申请号：US15909857
申请日：2018-03-01
申请人： Amnio Technology LLC
摘要： An enriched amnion derived tissue graft has a stromal matrix layer and an epithelium layer. A stromal matrix layer may contain a basement membrane layer, a compact layer, a fibroblast layer, and an intermediate layer. An amnion derived tissue graft may have a plurality of tissue layers and the layers may be configured with the epithelium layers toward the inside and the stromal matrix layers toward the outside surface. An enriched portion may be coated onto or be configured within a tissue layer and have an increased concentration of cells, of proteins, growth factors, seed cells, pharmaceuticals or any combination thereof. A carrier fluid such as amniotic fluid may be used to produce an enrichment composition for coating the tissue graft. The cells within the enriched portion may be stem cells from the amnion, or cells from other tissue and may be seed cells selected based on the treatment location.
-
公开(公告)号：US20170095515A1
公开(公告)日：2017-04-06
申请号：US15381044
申请日：2016-12-15
申请人： Amnio Technology LLC
IPC分类号： A61K35/50 , A61K9/14 , A61K47/20 , A61F9/00 , A61J1/14 , A61M11/00 , A61M5/178 , A61K35/545 , A61K47/46
CPC分类号： A61K35/50 , A61F9/0008 , A61J1/14 , A61J2200/44 , A61K8/0241 , A61K8/982 , A61K9/14 , A61K35/28 , A61K35/35 , A61K35/44 , A61K35/545 , A61K47/20 , A61K47/46 , A61K2800/244 , A61K2800/412 , A61M5/178 , A61M11/00 , A61Q19/08 , C12N5/0605 , A61K2300/00
摘要： A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at −20° C. for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.
-
4.发明申请METHOD OF TREATMENT UTILIZING AN ACELLULAR AMNION DERIVED THERAPEUTIC COMPOSITION 有权治疗使用丙种球蛋白衍生的治疗组合物的方法公开(公告)号：US20160199417A1
公开(公告)日：2016-07-14
申请号：US14853889
申请日：2015-09-14
申请人： Amnio Technology LLC
CPC分类号： A61K35/50 , A61K8/982 , A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/0046 , A61K9/0048 , A61K9/0053 , A61K9/06 , A61K35/28 , A61K35/35 , A61K35/44 , A61K2800/74 , A61Q19/00 , A61Q19/08 , A61K2300/00
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
摘要翻译： 描述了具有许多各种组成实施方案的无细胞羊膜衍生治疗组合物。 无细胞羊膜衍生的治疗组合物基本上没有活的或活跃的羊膜细胞。 羊膜细胞可能被破坏，细胞和细胞碎片可以从无细胞羊膜来源的治疗组合物中去除。 来自非细胞羊膜的治疗组合物可以包含微粉化的胎盘组织颗粒和/或羊水。 脱细胞羊膜衍生治疗组合物可以是与流体如血浆，盐水，羊水，其组合等组合的微粉化羊膜的分散体。 可将无细胞羊膜衍生的治疗组合物与基质组分组合以形成复合物。 来自非细胞羊膜的治疗组合物可以与包含活细胞如干细胞的组合物结合使用。
-
公开(公告)号：US11772200B2
公开(公告)日：2023-10-03
申请号：US17515964
申请日：2021-11-01
申请人： Amnio Technology LLC
发明人： Merrill Stromer , Larry Macal , Donald R. Taylor , Cris Holmes , James E. Ellis
IPC分类号： B23K26/38 , A61L27/36 , B23K26/402 , B25J11/00 , B25J9/16 , B25J13/08 , B23K37/04 , B23K26/082 , B25J9/02
CPC分类号： B23K26/38 , A61L27/3691 , B23K26/082 , B23K26/402 , B23K37/0408 , B25J9/1664 , B25J9/1697 , B25J11/0055 , B25J13/08 , B25J9/026
摘要： An allograft optimization system utilizes an optical system to determine the outer perimeter of a tissue blank for allograft cutting therefrom. The optical system determines an optimal allograft array pattern that can be derived from the irregular tissue blank and may include a plurality of various allograft shapes and sizes. A computer operates an allograft optimization computer program that receives input regarding the outer perimeter of the tissue blank. A cutting implement, such as a laser, is configured to cut the allografts from the irregularly shaped tissue blank according the allograft array pattern. The cutting implement is automatically actuated by an actuator with respect to the tissue blank to cut the allografts therefrom. The cutting implement may be a laser or a galvo laser that is directed by one or more mirrors. The tissue may be birth tissue including placental tissue and amnion.
-
公开(公告)号：US11369643B2
公开(公告)日：2022-06-28
申请号：US16730877
申请日：2019-12-30
申请人： Amnio Technology LLC
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
-
公开(公告)号：US10517903B2
公开(公告)日：2019-12-31
申请号：US15542444
申请日：2015-09-14
申请人： Amnio Technology LLC
IPC分类号： A61L27/36 , A61K35/35 , A61K35/50 , A61K31/728
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
-
公开(公告)号：US20190350984A1
公开(公告)日：2019-11-21
申请号：US16525062
申请日：2019-07-29
申请人： Amnio Technology LLC
IPC分类号： A61K35/50 , A61K35/545 , A61K9/14 , A61K8/98 , A61K35/28 , A61F9/00 , A61M5/178 , A61M11/00 , A61J1/14 , A61K47/46 , A61K47/20 , A61Q19/08 , A61K8/02 , C12N5/073 , A61K35/44 , A61K35/35
摘要： A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at −20° C., for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.
-
公开(公告)号：US20220118027A1
公开(公告)日：2022-04-21
申请号：US17562839
申请日：2021-12-27
申请人： Amnio Technology LLC
摘要： An enriched amnion derived tissue graft has a stromal matrix layer and an epithelium layer. A stromal matrix layer may contain a basement membrane layer, a compact layer, a fibroblast layer, and an intermediate layer. An amnion derived tissue graft may have a plurality of tissue layers and the layers may be configured with the epithelium layers toward the inside and the stromal matrix layers toward the outside surface. An enriched portion may be coated onto or be configured within a tissue layer and have an increased concentration of cells, of proteins, growth factors, seed cells, pharmaceuticals or any combination thereof. A carrier fluid such as amniotic fluid may be used to produce an enrichment composition for coating the tissue graft. The cells within the enriched portion may be stem cells from the amnion, or cells from other tissue and may be seed cells selected based on the treatment location.
-
公开(公告)号：US20180271915A1
公开(公告)日：2018-09-27
申请号：US15542444
申请日：2015-09-14
申请人： Amnio Technology LLC
IPC分类号： A61K35/50 , A61K35/35 , A61K31/728
CPC分类号： A61K35/50 , A61K31/728 , A61K35/35 , A61L27/3604 , A61L27/3683
摘要： Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.022 秒)
